INOVIO PHARMACEUTICALS, INC.

Form 4 May 23, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

Washington, D.C. 20549

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations

may continue. See Instruction

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person *

Kim Jong Joseph

(First) (Middle)

1787 SENTRY PARKWAY WEST, BUILDING 18, SUITE 400

(Street)

BLUE BELL, PA 19422

2. Issuer Name and Ticker or Trading

Symbol

INOVIO PHARMACEUTICALS, INC. [INO]

3. Date of Earliest Transaction

(Month/Day/Year) 05/22/2014

4. If Amendment, Date Original

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

5. Amount of

Securities

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

below)

_X__ Director

Applicable Line)

X_ Officer (give title

(City) (State)

1. Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3)

(Zip)

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code (Instr. 8)

Disposed of (D) (Instr. 3, 4 and 5)

Beneficially Owned Following Reported (A) Transaction(s)

or (Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion

3. Transaction Date 3A. Deemed

5. Number of (Month/Day/Year) Execution Date, if TransactionDerivative

6. Date Exercisable and **Expiration Date**

7. Title and Amoun Underlying Securiti

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

5. Relationship of Reporting Person(s) to

(Check all applicable)

Chief Executive Officer

6. Ownership

Form: Direct

(I)

(Instr. 4)

6. Individual or Joint/Group Filing(Check

10% Owner

Other (specify

7. Nature of

Ownership

(Instr. 4)

Indirect

(D) or Indirect Beneficial

Estimated average

burden hours per

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

Security (Instr. 3)	Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Acquired (A) Disposed of (Instr. 3, 4, an 5)	or D)			4)
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amou Numb Share
Common Stock Option	\$ 2.2	05/22/2014		A	340,000	05/22/2014(1)	05/22/2024	Common Stock	340,

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting owner rune, runess	Director	10% Owner	Officer	Other		
Kim Jong Joseph						
1787 SENTRY PARKWAY WEST BUILDING 18, SUITE 400	X		Chief Executive Officer			

Signatures

BLUE BELL, PA 19422

/s/ Jong Joseph
Kim

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The vesting schedule for 340,000 options is as follows: 85,000 shares vested on May 22, 2014; 85,000 shares will vest on May 22, 2015; 85,000 shares will vest on May 22, 2016; 85,000 shares will vest on May 22, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2